CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.
CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.
Professor F Drago of the University of Catania Medical School, Catania, Italy and colleagues injected [alpha]-chymotrypsin into rabbit eyes to induce ocular hypertension, and then assessed the effects of administering CORM-3 at doses of 0.001, 0.01, 0.1 and 1%. In a separate trial arm, the team induced ocular hypertension through subconjunctival betamethasone injections and administered CORM-3. In each trial arm, control subjects were treated with inactive CORM-3 (iCORM-3).
In both trial arms, administration of CORM-3 was associated with a reduction in IOP; dosage amount was positively correlated with the amount of IOP reduction. The control subjects experienced no IOP reduction.
The researchers therefore concluded that CORM-3 is associated with a reduction of IOP in two separate animal models of induced ocular hypertension. This correlation between carbon monoxide modulation and IOP has been established by previous studies.
ARxVision, Seeing AI, NaviLens announce partnership for headset programme
April 1st 2024The UK's Royal National Institute of Blind People is the global distributor of the headset and ARxVision is partnering with the National Federation of the Blind and Vision Australia to expand global accessibility